Common Contracts
13 similar Underwriting Agreement contracts by ImmunoCellular Therapeutics, Ltd., Agrify Corp, Axion Power International, Inc., others
●] UNITS EACH UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK MED-X, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 9th, 2024 • Med-X, Inc. • Pharmaceutical preparations • New York
The undersigned, MED-X, INC., a company incorporated under the laws of Nevada (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which MAXIM GROUP LLC (“Maxim”) is acting as representative to the several Underwriters (in such capacity, the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
UNDERWRITING AGREEMENT betweenUnderwriting Agreement • May 5th, 2022 • New York
The undersigned, The Alkaline Water Company Inc., a Nevada corporation (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of The Alkaline Water Company, Inc., the "Company"), hereby confirms its agreement (this "Agreement") with Aegis Capital Corp. (hereinafter referred to as "you" (including its correlatives) or the ("Underwriter") as follows:
BLUE WATER VACCINES, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 8th, 2022 • Blue Water Vaccines Inc. • Pharmaceutical preparations • New York
The undersigned, Blue Water Vaccines, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Boustead Securities, LLC is acting as representative (in such capacity, the “Representative”), an aggregate of 2,222,222 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”) The offering and sale of the Shares contemplated by this Agreement is referred to herein as the “Offering.”
UNDERWRITING AGREEMENTUnderwriting Agreement • February 19th, 2021 • Agrify Corp • Agricultural services • New York
The undersigned, Agrify Corporation, a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Agrify Corporation, the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Maxim Group LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
UNDERWRITING AGREEMENTUnderwriting Agreement • February 11th, 2021 • Agrify Corp • Agricultural services • New York
The undersigned, Agrify Corporation, a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of Agrify Corporation, the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representative (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Maxim Group LLC is acting as representative to the several Underwriters (the “Representative” and if there are no Underwriters other than the Representative, references to multiple Underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.
HALL OF FAME RESORT & ENTERTAINMENT COMPANY UNDERWRITING AGREEMENTUnderwriting Agreement • February 5th, 2021 • Hall of Fame Resort & Entertainment Co • Services-miscellaneous amusement & recreation • New York
The undersigned, Hall of Fame Resort & Entertainment Company, a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), an aggregate of ________ shares (the “Firm Shares”) of common stock, par value $0.0001 per share (the “Common Stock”) and, at the election of the Representative, up to an additional ________ shares of Common Stock (the “Option Shares” and collectively with the Firm Shares, the “Shares” or the “Securities”). The offering and sale of the Securities contemplated by this Agreement is referred to herein as the “Offering.”
BIOCARDIA, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • July 23rd, 2019 • BioCardia, Inc. • Biological products, (no disgnostic substances) • New York
The undersigned, BioCardia, Inc., a Delaware corporation (the “Company”), hereby confirms its agreement (this “Agreement”) to issue and sell to the underwriter or underwriters, as the case may be, named in Schedule I hereto (each, an “Underwriter” and, collectively, the “Underwriters;”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), an aggregate of ______________ units (the “Firm Units” or “Units”) of the Company’s securities, and, at the election of the Representative, up to an additional ____________ Option Shares (as defined herein and collectively with the shares of Common Stock underlying the Firm Units, the “Shares”), and/or up to an additional ___________ Option Warrants (as defined herein and collectively with warrants underlying the Firm Units, the “Warrants”). Each Unit consists of one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and one Warrant. Each Warrant entitles the holder to purcha
FARMMI, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 15th, 2017 • Farmmi, Inc. • Canned, fruits, veg, preserves, jams & jellies • Florida
The undersigned, Farmmi, Inc., a Cayman Islands exempted company (the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, for whom ViewTrade Securities, Inc. is acting as representative (in such capacity, the “Representative,” if there are no underwriters other than the Representative, reference to multiple underwriters shall be disregarded and the term Representative as used herein shall have the same meaning as underwriter, the “Underwriters” and each an “Underwriter”) to issue and sell to the Underwriters an aggregate of [●] ordinary shares, par value $0.001, of the Company (“Shares”). The offering and sale of securities contemplated by this Agreement is referred to herein as the “Offering.”
IMMUNE PHARMACEUTICALS INC. UNDERWRITING AGREEMENTUnderwriting Agreement • October 11th, 2017 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York
IMMUNOCELLULAR THERAPEUTICS, LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • July 13th, 2017 • ImmunoCellular Therapeutics, Ltd. • Pharmaceutical preparations • New York
ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule A hereto (the “Underwriters,” or each, an “Underwriter”), for whom Maxim Group LLC is acting as representative (the “Representative”), an aggregate of 5,000 units (“the “Units”) each consisting of: (i) one share of the Company’s Series B 8.0% mandatorily convertible preferred stock, $0.0001 par value per share (the “Preferred Stock”) (each a “Share” and, collectively, the “Shares”) convertible into shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (the “Conversion Shares”), (ii) 0.6 of a Series 1 Warrant (the “Series 1 Warrants”) to purchase one share of Preferred Stock, (iii) 0.6 of a Series 2 Warrant (the “Series 2 Warrants”) to purchase one share of Preferred Stock, and (iv) 0.6 of a Series 3 Warrant (the “Series 3 Warrants,” and together with the Series 1 W
IMMUNOCELLULAR THERAPEUTICS, LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • July 10th, 2017 • ImmunoCellular Therapeutics, Ltd. • Pharmaceutical preparations • New York
ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule A hereto (the “Underwriters,” or each, an “Underwriter”), for whom Maxim Group LLC is acting as representative (the “Representative”), an aggregate of 5,000 units (“the “Units”) each consisting of: (i) one share of the Company’s Series B 8.0% mandatorily convertible preferred stock, $0.0001 par value per share (the “Preferred Stock”) (each a “Share” and, collectively, the “Shares”) convertible into shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (the “Conversion Shares”), (ii) 0.6 of a Series 1 Warrant (the “Series 1 Warrants”) to purchase one share of Preferred Stock, (iii) 0.6 of a Series 2 Warrant (the “Series 2 Warrants”) to purchase one share of Preferred Stock, and (iv) 0.6 of a Series 3 Warrant (the “Series 3 Warrants,” and together with the Series 1 W
IMMUNOCELLULAR THERAPEUTICS, LTD. UNDERWRITING AGREEMENTUnderwriting Agreement • August 3rd, 2016 • ImmunoCellular Therapeutics, Ltd. • Pharmaceutical preparations • New York
ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of: (i) [ ] shares (“Firm Shares”) of the Company’s common stock, $0.0001 par value per share (“Shares”), (ii) [ ] warrants to purchase [ ] Shares at an exercise price equal to $[ ] per share (“Base Warrants”), and (iii) [ ] warrants to purchase [ ] Shares at an exercise price equal to $0.01 per share (“Pre-Funded Warrants”) to the several underwriters (such underwriters, for whom Maxim Group LLC (“Maxim” or the “Representative”) is acting as representative, the “Underwriters” and each an “Underwriter”). Each Share shall be sold together with a Base Warrant to purchase 0.75 of a share of common stock; or, alternatively, each Pre-Funded Warrant shall be sold, in lieu of a Share, together with a Base Warrant to purchase 0.75 of a share of common stock. Such [ ] Base Warrants and [ ] Pre-Funded Warrants are hereinafter colle
AXION POWER INTERNATIONAL, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • September 15th, 2014 • Axion Power International, Inc. • Miscellaneous electrical machinery, equipment & supplies • New York
Axion Power International, Inc., a Delaware corporation (the “Company”), confirms its agreement, subject to the terms and conditions set forth herein, with each of the underwriters listed on Schedule A hereto (collectively, the “Underwriters”), for whom Maxim Group LLC is acting as representative (in such capacity, the “Representative”), to sell and issue to the Underwriters an aggregate of _______ shares (the “Firm Shares”) of common stock, par value $.005 per share, of the Company (the “Common Stock”), together with warrants to purchase an aggregate of _______ shares of Common Stock at an exercise price equal to $_______ per share (each a “Firm Warrant” and collectively, the “Firm Warrants”). Each Firm Share shall be accompanied by a Firm Warrant to purchase one additional share of Common Stock.
